Venigalla Rao at CUA Gets Gates Foundation Grant to Develop T4 as a Vector For HIV Vaccination.
BioControl has been purchased by Targeted Genetics. Biocontrol will start to do work against bacterial infections.
OmniLytics has relocated from Salt Lake City to Sandy, Utah, US to expand its manufacturing capabilities. In 2010 OmniLytics produced nearly 100,000 litres of bacteriophage product and moving to a site with 60,000 sq ft (from 10,000) of lab and manufacturing space will support continued growth.
Justin Reber, CEO of OmniLytics, said: “This move not only significantly increases our manufacturing capabilities, but also provides the potential for future expansion onto an additional seven acres of undeveloped property acquired adjacent to the four acre, two building campus.”
OmniLytics is also nearing completion of a master plan for the production facility. This will provide equipment to support production of millions of litres of bacteriophage final product a year.
In September, St. Hilda’s College at Oxford is having their first bacteriophage conference. Oxford Bacteriophage Meeting 2011.
Our keynote speaker from last year was nominated by the Department of Defense.
Old phage site: http://acdrupal.evergreen.edu/phage/ (last update 2009)
Dr. Jason Gill, who for the last several years has been the Program Director at the Center for Phage Technology at Texas A&M, is now taking a faculty position affiliated with the Center in the Department of Animal Science at Texas A&M.
AmpliPhi has just signed a Collaborative Research and Development Agreement (CRADA) with the US Army Medical Research and Development Command and the Walter Reed Army Institute of Research for developing and commercializing phage-based therapies to treat drug-resistant bacterial infections.
Wall Street Journal